I know, that's why I mentioned potential not being priced in and FOMO. That share price is reflective of only revenue and a big pharma P/E. A 50 P/E would not surprise me at all. Within a year of the EUA we should have HIV and longhaulers approval and other catalysts then the craziness really begins.